Arcutis Biotherapeutics, Inc. (ARQT) Stock Analysis: Exploring a 30.94% Potential Upside Amidst Robust Revenue GrowthArcutis Biotherapeutics, Inc. (NASDAQ: ARQT), a prominent player in the healthcare sector, specifically within the biotechnology industry, stands as a compelling prospect for investors seeking exposure to innovative dermatological treatments. Currently trading at $17.375, Arcutis’s stock price has maintained its position within a 52-week range of $8.31 to $17.93, reflecting a period of significant volatility and growth potential. Despite these growth indicators, Arcutis faces challenges typical of biopharmaceutical companies in their growth phases. Analysts have set a target price range of $19.00 to $29.00, with an average target of $22.75, suggesting a potential upside of 30.94% from the current price. Arcutis Biotherapeutics continues to be a fascinating case for investors who are willing to embrace some risk in exchange for potential high rewards in the biotech sector.